ATE188479T1 - Verzweigte oligonukleotide als pathogenhemmende mittel - Google Patents

Verzweigte oligonukleotide als pathogenhemmende mittel

Info

Publication number
ATE188479T1
ATE188479T1 AT95920668T AT95920668T ATE188479T1 AT E188479 T1 ATE188479 T1 AT E188479T1 AT 95920668 T AT95920668 T AT 95920668T AT 95920668 T AT95920668 T AT 95920668T AT E188479 T1 ATE188479 T1 AT E188479T1
Authority
AT
Austria
Prior art keywords
sequences
pathogen
different
pathogene
oligonucleotides
Prior art date
Application number
AT95920668T
Other languages
English (en)
Inventor
Sudhir Agrawal
Susan Meschwitz
Original Assignee
Hybridon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hybridon Inc filed Critical Hybridon Inc
Application granted granted Critical
Publication of ATE188479T1 publication Critical patent/ATE188479T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C12N15/1132—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against retroviridae, e.g. HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/317—Chemical structure of the backbone with an inverted bond, e.g. a cap structure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/52—Physical structure branched

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • AIDS & HIV (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
AT95920668T 1994-06-01 1995-05-30 Verzweigte oligonukleotide als pathogenhemmende mittel ATE188479T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25249494A 1994-06-01 1994-06-01
PCT/US1995/006720 WO1995032986A1 (en) 1994-06-01 1995-05-30 Branched oligonucleotides as pathogen-inhibitory agents

Publications (1)

Publication Number Publication Date
ATE188479T1 true ATE188479T1 (de) 2000-01-15

Family

ID=22956248

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95920668T ATE188479T1 (de) 1994-06-01 1995-05-30 Verzweigte oligonukleotide als pathogenhemmende mittel

Country Status (9)

Country Link
US (1) US6489464B1 (de)
EP (1) EP0763050B1 (de)
JP (1) JPH10504184A (de)
KR (1) KR970703357A (de)
AT (1) ATE188479T1 (de)
AU (1) AU2604995A (de)
CA (1) CA2190998A1 (de)
DE (1) DE69514351T2 (de)
WO (1) WO1995032986A1 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030099959A1 (en) * 1995-04-12 2003-05-29 Kandimalla Ekambar R. Cooperative oligonucleotides
US6776986B1 (en) 1996-06-06 2004-08-17 Novartis Ag Inhibition of HIV-1 replication by antisense RNA expression
US5886165A (en) * 1996-09-24 1999-03-23 Hybridon, Inc. Mixed backbone antisense oligonucleotides containing 2'-5'-ribonucleotide- and 3'-5'-deoxyribonucleotides segments
KR20000065690A (ko) * 1999-04-08 2000-11-15 박종구 반응 특이성 및 안정성을 개선시킨 안티센스 올리고 뉴클레오타이드, 안티센스 ｄｎａ 및 그 제조방법
US9994853B2 (en) 2001-05-18 2018-06-12 Sirna Therapeutics, Inc. Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
US7276489B2 (en) * 2002-10-24 2007-10-02 Idera Pharmaceuticals, Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends
EP1741781A3 (de) * 2002-02-20 2007-06-06 Sirna Therapeutics, Inc. Behandlung von Alzheimer-Krankheit durch RNA-Interferenz unter Verwendung von short interfering nucleic acid (siNA)
US9181551B2 (en) 2002-02-20 2015-11-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US9657294B2 (en) 2002-02-20 2017-05-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
WO2004015075A2 (en) * 2002-08-08 2004-02-19 Dharmacon, Inc. Short interfering rnas having a hairpin structure containing a non-nucleotide loop
CA2528963A1 (en) * 2003-06-27 2005-01-13 Sirna Therapeutics, Inc. Rna interference mediated treatment of alzheimer's disease using short interfering nucleic acid (sina)
US10508277B2 (en) 2004-05-24 2019-12-17 Sirna Therapeutics, Inc. Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
CA2572472C (en) 2004-07-01 2013-08-13 Gen-Probe Incorporated Methods and compositions to detect nucleic acids in a biological sample
US10316352B2 (en) * 2008-05-13 2019-06-11 Gen-Probe Incorporated Methods of capturing a target nucleic acid for amplification and detection using an inactivatable target capture oligomer
CN102292457B (zh) * 2008-11-25 2014-04-09 简·探针公司 检测小rna的组合物和方法及其用途
EP2470656B1 (de) 2009-08-27 2015-05-06 Idera Pharmaceuticals, Inc. Zusammensetzung zur genexpressionshemmung und ihre anwendungen
WO2012058210A1 (en) 2010-10-29 2012-05-03 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
US8877722B2 (en) 2011-03-25 2014-11-04 Idera Pharmaceuticals, Inc. Compositions for inhibiting gene expression and uses thereof
US20160319278A1 (en) 2015-04-03 2016-11-03 University Of Massachusetts Fully stabilized asymmetric sirna
DE102015008536A1 (de) 2015-07-02 2017-01-05 Rheinische Friedrich-Wilhelms-Universität Bonn Diskontinuierliche Oligonukleotid-Liganden
WO2017030973A1 (en) 2015-08-14 2017-02-23 University Of Massachusetts Bioactive conjugates for oligonucleotide delivery
US10478503B2 (en) * 2016-01-31 2019-11-19 University Of Massachusetts Branched oligonucleotides
EP3825400B1 (de) * 2016-04-08 2024-12-25 Translate Bio, Inc. Multimere codierende nukleinsäure und verwendungen davon
CA3033368A1 (en) 2016-08-12 2018-02-15 University Of Massachusetts Conjugated oligonucleotides
JP7406793B2 (ja) 2017-06-23 2023-12-28 ユニバーシティー オブ マサチューセッツ ２テイル自己デリバリー型ｓｉＲＮＡおよび関連方法
WO2020033899A1 (en) 2018-08-10 2020-02-13 University Of Massachusetts Modified oligonucleotides targeting snps
US11279930B2 (en) 2018-08-23 2022-03-22 University Of Massachusetts O-methyl rich fully stabilized oligonucleotides
CN113614232A (zh) 2019-01-18 2021-11-05 马萨诸塞大学 动态药代动力学修饰锚
KR20220047989A (ko) 2019-08-09 2022-04-19 유니버시티 오브 매사추세츠 Snp를 표적화하는 화학적으로 변형된 올리고뉴클레오타이드
US12365894B2 (en) 2019-09-16 2025-07-22 University Of Massachusetts Branched lipid conjugates of siRNA for specific tissue delivery
WO2021242883A1 (en) 2020-05-26 2021-12-02 University Of Massachusetts Synthetic oligonucleotides having regions of block and cluster modifications
CN117677699A (zh) 2021-06-23 2024-03-08 马萨诸塞大学 用于治疗先兆子痫和其他血管生成病症的优化抗flt1寡核苷酸化合物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5194428A (en) * 1986-05-23 1993-03-16 Worcester Foundation For Experimental Biology Inhibition of influenza virus replication by oligonucleotide phosphorothioates
US4806403A (en) 1987-12-23 1989-02-21 Gilbert Lemire Decorative module having a concave face
JPH04501052A (ja) * 1988-02-26 1992-02-27 ザ・ウスター・フアウンデーシヨン・フオー・バイオメデイカル・リサーチ 外来性オリゴヌクレオチドによるｈｔｌｖ―３の抑制
US5399676A (en) 1989-10-23 1995-03-21 Gilead Sciences Oligonucleotides with inverted polarity
US5215899A (en) * 1989-11-09 1993-06-01 Miles Inc. Nucleic acid amplification employing ligatable hairpin probe and transcription
NZ239372A (en) * 1990-08-15 1997-06-24 Genta Inc Inhibition of herpes virus infection by antisense oligomers
JPH06501162A (ja) * 1990-09-21 1994-02-10 ユニバーシティ オブ メリーランド ウイルス類の成長または複製を抑制するための組成物および方法
CA2126979A1 (en) * 1991-12-31 1993-07-22 Eliezer Rapaport Antiparasitic oligonucleotides active against drug resistant malaria
US5646261A (en) * 1992-01-22 1997-07-08 Hoechst Aktiengesellschaft 3'-derivatized oligonucleotide analogs with non-nucleotidic groupings, their preparation and use
US5543507A (en) * 1992-03-05 1996-08-06 Isis Pharmaceuticals, Inc. Covalently cross-linked oligonucleotides
EP0649466A1 (de) * 1992-07-02 1995-04-26 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Verfahren zur hemmung von viraler replikation

Also Published As

Publication number Publication date
KR970703357A (ko) 1997-07-03
US6489464B1 (en) 2002-12-03
EP0763050A1 (de) 1997-03-19
DE69514351T2 (de) 2000-08-10
CA2190998A1 (en) 1995-12-07
DE69514351D1 (de) 2000-02-10
JPH10504184A (ja) 1998-04-28
WO1995032986A1 (en) 1995-12-07
EP0763050B1 (de) 2000-01-05
AU2604995A (en) 1995-12-21

Similar Documents

Publication Publication Date Title
ATE188479T1 (de) Verzweigte oligonukleotide als pathogenhemmende mittel
WO1995032986B1 (en) Branched oligonucleotides as pathogen-inhibitory agents
ATE138384T1 (de) Olionukleotidalkylphosphonate und - phosphonothioate
ES2556243T3 (es) Agentes terapéuticos que contienen bacteriófagos
EP1325019A4 (de) Antisense-modulation der clusterinexpression
EP1248791A4 (de) Antisens-modulierung der caspase 3 expression
CA2210353A1 (en) Stabilized external guide sequences
CA2265917A1 (en) Method for using oligonucleotides having modified cpg dinucleosides
WO2001055341A3 (en) Immunomodulatory polynucleotides in treatment of an infection by an intracellular pathogen
NO952863D0 (no) Fluoxetin-farmasöytiske sammensetninger
CA2202280A1 (en) Sugar modified nucleosides and their use for synthesis of oligonucleotides
KR950702626A (ko) 치료제로서 자체-안정화된 올리고누클레오티드(self-stabilized loigonucleotides as therapeutic agents)
EP2329830A3 (de) Antisense-Hemmung der PTP1B-Expression
EP1417351A4 (de) Antisense-modulation der expression von apolipoprotein(a)
EP1250157A4 (de) Antisens-modulation der expression der induzierbaren stickstoffmonoxid-synthase
WO2000046359A3 (en) Medicament
NO20006631L (no) Forbindelser oppnådd fra salvie-arter med antiviral aktivitet
ATE157370T1 (de) Oligonukleotide mit wirkung gegen das respiratorische synzytial virus
WO1995003406A3 (en) Enhancement of oligonucleotide inhibition of protein production, cell proliferation, and/or multiplication of infectious disease pathogens
SE9503117D0 (sv) Novel use of padlock probes
EP1114826A3 (de) Antibakterielle und prokinetische Makroliden
WO2000040592A8 (en) Acid stable backbone modified end-blocked nucleic acids and therapeutic uses thereof
FR2792320B1 (fr) Nouveaux amides aromatiques substitues par un ribose, leur procede de preparation et leur application comme medicaments
EP1163373A4 (de) Antisense-modulation des zellulären hemmstoffs der apoptosis-expression
CA2332686A1 (en) Novel 13 and 14-membered antibacterial and prokinetic macrolides and their intermediates

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties